Page last updated: 2024-12-08

bisnortilidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

bisnortilidine: active metabolite of tilidine; structure given in first source; RN given refers to (trans(+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID521475
SCHEMBL ID16815218
MeSH IDM0172931

Synonyms (8)

Synonym
ethyl 2-amino-1-phenyl-3-cyclohexene-1-carboxylate
bisnortilidin
bisnortilidine
ethyl 2-amino-1-phenylcyclohex-3-ene-1-carboxylate
FT-0663357
ethyl 2-amino-1-phenyl-3-cyclohexene-1-carboxylate, trans-(.+/-.)-
BTKAMSWFNMGLGM-UHFFFAOYSA-N
SCHEMBL16815218

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The systemic bioavailability of tilidine was low (7."( Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine.
Hajda, JP; Jähnchen, E; Oie, S; Trenk, D, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Thus, although two-thirds of the dose of tilidine is metabolized to nortilidine, only one-third of the dose is available systemically as nortilidine for interaction with the opiate receptors after both intravenous and oral dosing of tilidine."( Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine.
Hajda, JP; Jähnchen, E; Oie, S; Trenk, D, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's1 (9.09)18.2507
2000's4 (36.36)29.6817
2010's5 (45.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (36.36%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (18.18%)4.05%
Observational1 (9.09%)0.25%
Other4 (36.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]